Project Grant R42DA056084
Award Date
7/15/25
Completion Date
7/31/28
Dollars Obligated
$671K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...
This Project Grant award of $399,483, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to leverage synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel polypharmacological therapeutics for substance use disorders (SUDs). The key objectives are to generate multivalent compounds that can simultaneously target and restore imbalances in the opioid, dopaminergic, and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $798,828 to Dark Matter Therapeutics, Inc. to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The funded project will leverage artificial intelligence (AI) to develop an integrated drug discovery platform called M3.AI that combines target-based and phenotype-based methodologies. The goal...
The National Institute on Drug Abuse (NIDA) awarded a $959,964 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Charles River Analytics, Inc. to design and demonstrate the feasibility of a prototype system called Stimulant Use Recovery via Immersive Virtual Environments (SURVIVE). The goal of SURVIVE is to provide controlled environmental triggers and cognitive behavioral therapy (CBT) embedded into virtual environments to treat stimulant use disorder (STUD),...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This Project Grant award of $591,032 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Square2 Systems Inc. in Hanover, NH. The funding will support the development of the "COGITO" platform, a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment, and management of substance use disorders and other behavioral health conditions. The...
This three-year, $760,000 project grant from the National Institute on Drug Abuse will support the development of novel therapeutic lead compounds for stimulant use disorder. Funded under the Drug Abuse and Addiction Research Programs (CFDA 93.279), the award to West Virginia University Research Corporation will focus on chemical synthesis innovations to produce analogs of illudalic acid, a potent and irreversible inhibitor of protein tyrosine phosphatase receptor type D (PTPRD). PTPRD has...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $257,522 Project Grant (R25DA061764) to the University of Mississippi to develop a multimodal and interdisciplinary data science training program. The program aims to enhance a diverse workforce for addiction research by providing specialized training in artificial intelligence (AI) and machine learning (ML) methods. Key program components include webinars, summer...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...